42280. Source: A Tseng, Pharm D, Immunodeficiency Clinic, The Toronto Hospital, Department of Pharmacy, University of Toronto; S Walmsley, MD, Immunodeficiency Clinic, The Toronto Hospital, Department of Medicine, University of Toronto, Toronto ON. MORE ON MANAGEMENT STRATEGIES FOR CANDIDATES FOR PROTEASE INHIBITORS AND REQUIRING TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS In the preceding article...

Abstract Background Disseminated Mycobacterium marinum infections occur rarely, in immunocompromised patients. Treatment with a prolonged multi-drug regimen exposes patients to drug–drug interactions and side effects. Case report We case of disseminated M. infection 54-year-old renal transplant, HIV-infected woman. Manifestations the were cutaneous subcutaneous nodules, mediastinal lymph nodes ...

Rifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects of SLCO1B1 polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioav...

Background Interaction between M.avium and HIV drugs is unavoidable in HIV patients as for an improved life expectancy of HIV patients, additional medications have to be administered along with HIV drugs. The anti-M.avium drug rifabutin and protease inhibitor, ritonavir are associated with significant drug interactions involving the cytochrome P450 (CYP) enzyme system. Little information is ava...

Mycobacterium abscessus exhibits arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in M. infection models, implying that RBT might not be inactivated by Arr.

The in vitro intracellular effect of clarithromycin, amoxicillin, metronidazole, lansoprazole, and rifabutin, tested at concentrations corresponding to one times the MIC, two times the MIC, and four times the MIC, was evaluated against an invasive Helicobacter pylori strain. At four times the MIC, clarithromycin showed an early bactericidal effect within 4 h of incubation and, in determining th...

Intracellular concentrations of isoniazid and rifabutin resulting from administration of inhalable microparticles of these drugs to phorbol-differentiated THP-1 cells and the pharmacokinetics and biodistribution of these drugs upon inhalation of microparticles or intravenous administration of free drugs to mice were investigated. In cultured cells, both microparticles and dissolved drugs establ...

Background: Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for Helicobacter pylori (HP) infection, but it has not been analysed as a second-line treatment. Therefore, we seek to compare the effectiveness of a treatment regimen including rifabutin versus conventional quadruple therapy (QT). Methods/Design: Open clinical trial, randomised and m...